These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18638638)

  • 1. Gadolinium is not deposited in the skin of patients with normal renal function after exposure to gadolinium-based contrast agents.
    Boyd AS; Sanyal S; Abraham JL
    J Am Acad Dermatol; 2008 Aug; 59(2):356-8. PubMed ID: 18638638
    [No Abstract]   [Full Text] [Related]  

  • 2. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?
    Thomsen HS; Morcos SK; Dawson P
    Clin Radiol; 2006 Nov; 61(11):905-6. PubMed ID: 17018301
    [No Abstract]   [Full Text] [Related]  

  • 3. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors.
    Khurana A; Greene JF; High WA
    J Am Acad Dermatol; 2008 Aug; 59(2):218-24. PubMed ID: 18538448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts.
    Varani J; DaSilva M; Warner RL; Deming MO; Barron AG; Johnson KJ; Swartz RD
    Invest Radiol; 2009 Feb; 44(2):74-81. PubMed ID: 19077912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.
    Kribben A; Witzke O; Hillen U; Barkhausen J; Daul AE; Erbel R
    J Am Coll Cardiol; 2009 May; 53(18):1621-8. PubMed ID: 19406336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nephrogenic systemic fibrosis].
    Breitschaft A; Stahlmann R
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal failure and gadolinium. The number of documented cases is rising.
    Prescrire Int; 2008 Oct; 17(97):205. PubMed ID: 19537311
    [No Abstract]   [Full Text] [Related]  

  • 8. MRI gadolinium-based contrast agents. Radiologists beware!
    Goullé JP; Cattanéo A; Saussereau E; Mahieu L; Guerbet M; Lacroix C
    Ann Pharm Fr; 2009 Sep; 67(5):335-9. PubMed ID: 19695369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute phase reaction to gadolinium-DTPA in dialysis patients.
    Steen H; Giannitsis E; Sommerer C; Bahner U; Brandl M; Merbach C; Merten C; Ritz E; Katus HA; Zeier M; Schwenger V
    Nephrol Dial Transplant; 2009 Apr; 24(4):1274-7. PubMed ID: 19042926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of nonenzymatic glycosylation on the magnetic resonance imaging (MRI) contrast agent binding to human serum albumin.
    Henoumont C; Laurent S; Muller RN; Vander Elst L
    J Med Chem; 2012 Apr; 55(8):4015-9. PubMed ID: 22420713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nephrogenic systemic fibrosis and use of MR contrast media].
    Christiansen RE; Sviland L; Sekse I; Svarstad E
    Tidsskr Nor Laegeforen; 2009 Jan; 129(3):180-2. PubMed ID: 19180161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrogenic systemic fibrosis: more questions and some answers.
    Morcos SK; Thomsen HS
    Nephron Clin Pract; 2008; 110(1):c24-31; discussion c32. PubMed ID: 18688172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD; Bernheisel CR
    Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient widespread blood-brain barrier alterations after cerebral photothrombosis as revealed by gadofluorine M-enhanced magnetic resonance imaging.
    Stoll G; Kleinschnitz C; Meuth SG; Braeuninger S; Ip CW; Wessig C; Nölte I; Bendszus M
    J Cereb Blood Flow Metab; 2009 Feb; 29(2):331-41. PubMed ID: 18957988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA.
    Tamada T; Ito K; Sone T; Yamamoto A; Yoshida K; Kakuba K; Tanimoto D; Higashi H; Yamashita T
    J Magn Reson Imaging; 2009 Mar; 29(3):636-40. PubMed ID: 19243060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadolinium and kidney disease: are your patients at risk?
    Hollister D
    Nephrol Nurs J; 2008; 35(2):196-7. PubMed ID: 18472687
    [No Abstract]   [Full Text] [Related]  

  • 17. Nephrogenic systemic fibrosis: experimental studies confound prevailing theory of free gadolinium as a causative factor.
    Jakobsen J
    Acta Radiol; 2008 Jul; 49(6):616-7. PubMed ID: 18568551
    [No Abstract]   [Full Text] [Related]  

  • 18. Current status of gadolinium toxicity in patients with kidney disease.
    Perazella MA
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):461-9. PubMed ID: 19201920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproducibility of the aortic input function (AIF) derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the kidneys in a volunteer study.
    Mendichovszky IA; Cutajar M; Gordon I
    Eur J Radiol; 2009 Sep; 71(3):576-81. PubMed ID: 19004588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
    Idée JM; Port M; Dencausse A; Lancelot E; Corot C
    Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.